FAST NEWS: Ascentage’s manufacturing center gets EU stamp of approval
The latest: Ascentage Pharma Group International (6855.HK) announced on Tuesday it recently received a zero-deficiency report following a Good Manufacturing Practice (GMP) compliance audit of its global manufacturing center by…
Recent Articles
RELATED ARTICLES
-
BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
6855.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
BRIEF: Ascentage Pharma prices U.S. IPO at 20% discount, to raise up to $130 million
6855.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
